Serial Assessment of Fertility Experiences
About this study
The SAFE study is a long-term research project that watches people with sickle cell anemia (SCA) over time. The main goal is to see how a medicine called hydroxyurea affects their growth, puberty, and ability to have children. A second goal is to see how hydroxyurea affects pregnancy outcomes, by comparing people who take the medicine to those who don't.
- Condition
- Sickle Cell Anemia
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Who can join
- Age
- 8 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 7
- Minimum age: 8 years
- Study condition: Sickle Cell Anemia
- Patients with documented sickle cell anemia (SCA).
- At least 8 years of age at the time of enrollment.
- Enrolled on the EXTEND or SACRED study.
- Provide informed consent.
- Able to take part in all parts of the study, including treatments, check-ups, and follow-up visits.
Exclusion 2
- Currently taking part in another treatment study (not EXTEND or SACRED).
- Has received other treatments for sickle cell disease in the past 6 months.
Where
3 sites, 3 recruiting
Centro de Obstetricia y Ginecologia
Santo Domingo, Dominican Republic
Caribbean Institute for Health Research, University of West Indies
Kingston, Jamaica
Buganda Medical Centre
Mwanza, Tanzania
Contact
-
Teresa Latham, DrPh
513-803-7822 Teresa.Latham@cchmc.org
-
Russell E Ware, MD, PhD
513-803-4597 Russell.Ware@cchmc.org
Potential match only. Final eligibility is determined by the study team.